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qually toAbstract KP1339 is a promising ruthenium-based anticancer compound in early clinical
development. This study aimed to test the effects of KP1339 on the in vitro and in vivo activity
of the multi-kinase inhibitor sorafenib, the current standard ﬁrst-line therapy for advanced
hepatoma. Anticancer activity of the parental compounds as compared to the drug combina-
tion was tested against a panel of cancer cell lines with a focus on hepatoma. Combination of
KP1339 with sorafenib induced in the majority of all cases distinctly synergistic effects, com-
prising both sorafenib-resistant as well as sorafenib-responsive cell models. Several mecha-
nisms were found to underlie these multifaceted synergistic activities. Firstly, co-exposure
induced signiﬁcantly enhanced accumulation levels of both drugs resulting in enhanced apop-
tosis induction. Secondly, sorafenib blocked KP1339-mediated activation of P38 signalling
representing a protective response against the ruthenium drug. In addition, sorafenib treat-
ment also abrogated KP1339-induced G2/M arrest but resulted in check point-independent
DNA-synthesis block and a complete loss of the mitotic cell populations. The activity of
the KP1339/sorafenib combination was evaluated in the Hep3B hepatoma xenograft.
KP1339 monotherapy led to a 2.4-fold increase in life span and, thus, was superior to sorafe-
nib, which induced a 1.9-fold prolonged survival. The combined therapy further enhanced theed by Elsevier Ltd.
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P. Heﬀeter et al. / European Journal of Cancer 49 (2013) 3366–3375 3367mean survival by 3.9-fold. Synergistic activity was also observed in the VM-1 melanoma xeno-
graft harbouring an activating braf mutation. Together, our data indicate that the combina-
tion of KP1339 with sorafenib displays promising activity in vitro and in vivo especially against
human hepatoma models.
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.1. Introduction
Therapy with cytotoxic compounds or small molecule
inhibitors is a major strategy to treat human cancer at the
disseminated stage. Based on improved technological
possibilities during the last decades, the identiﬁcation
of tumour-speciﬁc alterations resulted in novel targeted
treatment strategies with improved eﬀectiveness. How-
ever, even for new targeted therapeutics, the occurrence
of drug resistance and unwanted side-eﬀects remains a
major obstacle for successful long-term treatment.1,2
Thus, in addition to the development of new drugs, espe-
cially the enhancement of activity by combination of
drugs is in the focus of clinical research.1 However,
besides cis- and oxaliplatin, metal drugs have been only
rarely included in such investigations. Recently, the
investigative anticancer ruthenium compound indazoli-
um trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
(KP1019) demonstrated promising anticancer activity
in a clinical phase I study with frequent disease stabilisa-
tion.3,4 Notably, only mild treatment-related toxicities
were observed, encouraging further clinical development
of KP1019.4 For better clinical application, the water-
soluble sodium salt of KP1019, termed KP1339, has been
recently developed and has recently successfully ﬁnished
a clinical phase I trial where profound activity especially
against neuroendocrine tumours (NET) were observed.5
Sorafenib (BAY 43-9006, Nexavar) is a multi-
targeted tyrosine kinase inhibitor that exerts potent
anti-angiogenic and antitumour activities. Sorafenib is
approved for the treatment of advanced renal cell carci-
noma as well as unresectable hepatocellular carcinoma
and is currently developed for other solid tumours.2,6
Initially, this small molecule inhibitor was identiﬁed as
an inhibitor of Raf serine/threonine kinases. Addition-
ally, it inhibits several oncogenic and/or pro-angiogenic
receptor tyrosine kinases, such as FMS-like tyrosine
kinase 3 (Flt3), the mast/stem cell growth factor recep-
tor (c-kit), the RET proto-oncogen, vascular endothelial
growth factor receptor (VEGFR) 1/2/3, and the platelet-
derived growth factor receptor (PDGFR) 1. However,
also some non-kinase targets for sorafenib have been
suggested.6–8 Recent studies demonstrated interference
of sorafenib with several cellular transport mechanisms
involved in drug resistance such as several ATP-binding
cassette (ABC) transporters or the non-ABC transporter
RLIP76.9,10 However, the impact of these eﬀects on the
activity and pharmacological characteristics of other
drugs remains widely unexplored. This study aimed toevaluate the activity of the combination between
KP1339 and sorafenib against solid human cancer cell
models in vitro and in vivo.
2. Material and methods
2.1. Chemicals
KP1339 was synthesised as published.11 Kinase
inhibitors were purchased from LC laboratories
(Woburn, United States of America [USA]). For
in vitro studies, the compounds were dissolved in
dimethyl sulfoxide (DMSO) (end-concentrations always
below 1%). All other substances were from Sigma–
Aldrich (St. Louis, USA).
2.2. Cell lines
The human cancer cell lines, their source as well as
the used cell culture media supplemented with 10% fetal
calf serum (PAA, Linz, Austria) are given in Supplemen-
tary Table 1. Cultures were periodically checked for
Mycoplasma contamination.
2.3. Cytotoxicity assays
Cell viability was determined by 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium (MTT) assay as pub-
lished.11,12 Cytotoxicity was calculated using the Graph
Pad Prism software (using a point-to-point function)
and was expressed as IC50 values calculated from full
dose–response curves (drug concentrations inducing a
50% reduction of cell number in comparison to untreated
control cells cultured in parallel). Synergism is expressed
by the combination index (CI) according to Chou and
Talalay13 using CalcuSyn software (Biosoft, Ferguson,
MO, USA). CI < 0.9, CI = 0.9–1.2 or CI >1.2 represent
synergism, additive eﬀects and antagonism, respectively.
2.4. Cell cycle analyses
Cell cycle distribution of drug-treated cells was deter-
mined by propidium iodide staining and ﬂow cytometry
as published.12
2.5. Total ruthenium (Ru) uptake levels
Intracellular Ru levels were determined as recently
described.11 A detailed description is included in Supple-
mentary material and methods.
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Total proteins were isolated and Western blots per-
formed as described.12 Primary antibodies used are
given in Supplementary Table 2. Additionally, second-
ary horseradish peroxidase-labelled antibodies (Santa
Cruz Biotechnology) were used at dilutions of 1:10000.2.7. Animals
Eight-week-old female CB-17 scid/scid (SCID) mice
were purchased from Harlan Laboratories (San Pietro
al Natisone, Italy). The animals were kept in a patho-
gen-free environment and every procedure was done in
a laminar airﬂow cabinet. Experiments were carried
out according to the Austrian and the Federation of
Laboratory Animal Science Associations (FELASA)
guidelines for animal care and protection.2.8. Xenograft experiments
Hep3B (106 with 10% matrigel) or VM-1 cells
(1.5  106) were injected subcutaneously into the right
ﬂank. When tumour nodules reached a mean size of
25 mm3, animals were treated with sorafenib orally (in
Cremophor EL, diluted in ethanol and then 1:10 with
deionised water), KP1339 intravenously (in citrate buﬀer
pH 3.5) or both. Tumour size was assessed by caliper
measurement. Tumour volume was calculated using
the formula: (length  width2)/2. The combined drug
eﬀects were assessed as tumour delay (Td) deﬁned as
the time in days to reach a tumour volume of 300 mm2.2.9. Quantiﬁcation of sorafenib
A new liquide chromatography- mass spectroscopy
(LC-MS) method has been established to detect the
intracellular accumulation of sorafenib. A detailed
description is included in Supplementary material and
methods.3. Results
3.1. Synergistic activity of KP1339 with sorafenib against
diverse malignant tumour types
The eﬀects of sorafenib on the anticancer activity of
KP1339 were tested in malignant cell lines of diverse ori-
gin with a focus on hepatoma (n = 12). Results obtained
are shown in Fig. 1 and in Supplementary Figs. S1–S3.
Most cell lines exhibited responsiveness to sorafenib
mono-treatment with a mean IC50 value below 10 lM
(Table 1). Only, in case of VL-8, Hep3B, HCC1.1 and
SW480 IC50 values >10 lM were observed. The IC50
values for KP1339 mono-therapy were between 45 and
200 lM (Table 1). For the drug combination, sorafenibco-treatment with KP1339 showed additive to strong
synergistic eﬀects in all cell lines investigated. Notably,
the combination of KP1339 with 10 lM sorafenib was
highly synergistic with CI values between 0.1 and 0.8
and especially KP1339 concentrations between 100 and
200 lM synergistically increased the anticancer activity
of sorafenib. Notably, the KP1339 and sorafenib drug
combination exhibited synergistic activity in sorafenib-
resistant (HCC1.1, Hep3B, VL-8 and VM-1) and
sorafenib-responsive cell lines (PLC/PRL/5, HepG2
and HCC2). This distinct synergism was in contrast to
several other kinase inhibitors. Thus, weak synergism
was also observed with (the VEGFR-1/2/3, PDGFR-ß
and c-kit inhibitor) sunitinib but not for axitinib (VEG-
FR1/2/3, PDGFRa/ß, c-kit) or vemurafenib (targeting
braf V600E). Distinct antagonism was observed with
(the abl, PDGFR3 and c-kit inhibitor) gleevec (Supple-
mentary Fig. 4).3.2. Eﬀects of sorafenib on KP1339-induced apoptosis
Morphological changes induced in Hep3B cells by the
mono-treatments or drug combination are shown in
Fig. 2A. The cells were analysed by 40,6-diamidino-2-
phenylindole (DAPI) staining to evaluate chromatin
condensation as a parameter for programmed cell death
induction (Fig. 2B). In accordance to already published
observations, sorafenib14 as well as KP133911 mono-
treatment induced apoptosis in a dose-dependent
manner. Combination of KP1339 with sorafenib
synergistically increased the number of apoptotic cells.
This was accompanied by enhanced poly(ADP-
ribosyl)polymerase (PARP) and caspase 7 cleavage
(Fig. 2C). Similar results were obtained using the
braf-mutated melanoma model VM-1 and the
NSCLC-model VL-8 (Fig. 2D and E). In addition to
the enhanced cell-death inducing potential, a distinct
loss of the mitotic cell population was found in all
combination-treated samples (Fig. 2B, right panel).3.3. Eﬀects of the KP1339/sorafenib combination on cell
cycle progression
Next, the eﬀects of the KP1339-sorafenib combina-
tion on cell cycle distribution were analysed. In several
investigated cell lines (Figs. 3A and Supplementary
Fig. S5), KP1339 treatment resulted in a distinct
increase of cells in G2/M phase. Sorafenib mono-
treatment also eﬀected cell cycle distribution leading to
an increase of cells either in G0/G1 or S phase. In the
combination settings sorafenib strongly suppressed the
KP1339-induced increase of cells in G2/M at all concen-
trations tested. We have previously reported that
treatment with KP1019 induces oxidative stress,15 which
is known to activate the P38 mitogen-activated protein
(MAP) kinase pathway16 and in turn G2/M cell cycle
PLC/PRF/5
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Fig. 1. Anticancer activity of KP1339 in combination with sorafenib. The indicated cell lines were treated for 72 h with KP1339 and sorafenib. Left
panel: Viability was evaluated by MTT assay. Values given are means ± standard deviations of one representative experiment performed in
triplicates. Right panel: combination index (CI) was calculated using CalcuSyn software (compare Section 2).
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KP1339-mediated P38 activation was analysed. As
shown in Fig. 3B and Supplementary Fig. S6, KP1339
treatment distinctly increased phosphorylation of P38,
which was inhibited by sorafenib cotreatment. A similar
eﬀect was also seen for the phosphorylation of the P38
downstream signalling proteins signal induce and activa-tor of transcription 3 (STAT3) and cAMP response
element-binding protein (CREB) (Fig. 3C). Consequently,
it was also tested whether the P38 inhibitor SD203580 or
the STAT3 inhibitor WP1066 synergise with KP1339.
Indeed, inhibition of P38 as well as its downstream
target STAT3 slightly increased the anticancer activity
of KP1339 (Fig. 3D and E).
Table 1
Anticancer activity of sorafenib and KP1339 monotreatment.
Tissue Cell line Sorafenib (lM) KP1339 (lM)
Mean SD Mean SD
Hepatoma Hep3B >10 – 186.3 ±6.0
HepG2 4.9 ±1.6 165.4 ±11.5
PLC/PRF/5 7.2 ±1.3 124.4 ±2.8
HCC1.1 >10 – >200 –
HCC2 2.7 ±0.3 69.4 ±5.8
Melanoma VM-1 9.5 ±0.2 178.3 ±10.2
VM-21 5.7 ±0.9 111.7 ±10.9
VM-48 9.7 ±0.2 143.8 ±12.4
Lung cancer A549 4.2 ±0.2 126.4 ±5.8
VL-8 >10 – 106.1 ±3.6
Colon cancer SW480 >10 – 74.3 ±1.3
HCT116 3.4 ±0.2 44.4 ±2.6
3370 P. Heﬀeter et al. / European Journal of Cancer 49 (2013) 3366–33753.4. Eﬀects of sorafenib cotreatment on intracellular Ru
accumulation and vice versa
Intracellular ruthenium levels were determined to
investigate whether sorafenib increases cellular KP1339
uptake. Sorafenib co-treatment signiﬁcantly enhanced
total KP1339 uptake in all tested cell lines (Fig. 4A).
With respect to the sorafenib accumulation, the combi-
nation of 75 lM KP1339 with 10 lM sorafenib induced
a 2.4-fold increase of the tyrosine kinase inhibitor in
Hep3B and a 1.6-fold increase in VM-1 cells (Fig. 4B).
These eﬀects were not based on general changes in cellu-
lar membrane integrity (Supplementary Figs. S7 and S8)
Notably, also combination experiments using the
panABC transporter inhibitor glibenclamide (GLI)
resulted in synergistic activity with both sorafenib as
well as KP1339 (Fig. 4C and Supplementary Fig. S9).
This indicates that competitive ABC transporter inhibi-
tion might be involved in the synergism of KP1339 with
sorafenib.3.5. Synergistic activity of KP1339 with sorafenib in vivo
The inﬂuence of KP1339 on the anti-hepatoma activ-
ity of sorafenib in vivo was tested using a Hep3B SCID
mouse xeno-transplantation model. All treatment
schemes were well tolerated and the mice did not exhibit
any symptoms of toxicity, such as fatigue, or signiﬁcant
weight loss (Supplementary Fig. 10A). With regard to
the anticancer activity, KP1339 as well as sorafenib
monotreatment induced a distinct delay in tumour
growth (Fig. 5A). Thus, Td values (day when tumour
volumes reached 300 mm3) increased from 22.8 days to
34.7 and 33.7 days, respectively. In the drug combina-
tion, a strong anti-tumour eﬀect was observed which
led to a Td value of 47 days. This pronounced antican-
cer activity resulted in life prolongation in all treated
groups (Fig. 5B): KP1339 treatment induced a 2.4-fold
increase in life span with a mean survival of 80 days ascompared to 33 days in the control group. Sorafenib
mono-treatment induced a 1.9-fold increase in survival
(60 days). Most importantly, the combined treatment
with KP1339 and sorafenib was most eﬀective with a sig-
niﬁcant increase in mean survival by 3.9-fold to 96 days.
Comparably, synergistic activity of KP1339 with sorafe-
nib was observed in braf V600E-positive VM-1 cells
(Fig. 5C). To evaluate whether the pronounced antican-
cer activity of the combination is based on enhanced
apoptosis induction, tumour samples of Hep3B-bearing
animals were collected after short time treatment (Sup-
plementary Fig. 10B) and analysed by hematoxylin/
eosin (H/E) staining. As shown in Fig. 5B, treatment
with the drug combination resulted in signiﬁcantly
increased apoptosis levels as well as decrease in cells dis-
playing mitotic features.4. Discussion
The multi-kinase inhibitor sorafenib is the current
standard therapeutic for advanced hepatoma. However,
tumour progression based on resistance development is
frequently observed after a few months of mono-
therapy2 implicating the need for combination strate-
gies. In this study, we demonstrated that the novel
ruthenium compound KP1339 distinctly enhances the
anticancer activity of sorafenib in vitro and in vivo.
Additionally, several molecular mechanisms underlying
this synergism were identiﬁed. Sorafenib mediates atten-
uation of KP1339-induced G2/M arrest and inhibits
activation of the protective P38 pathway. Additionally,
increased intracellular accumulation of both drugs was
observed in the combination setting. Together this
resulted in enhanced apoptosis induction and prolonged
disease control in vivo.
KP1339 is a novel ruthenium compound currently
tested with promising results in a clinical I/II trial.5
KP1339 treatment is known to generate intracellular
reactive oxygen species (ROS) probably caused by the
reduction-induced redox cycling15,20 and to induce
apoptosis via the mitochondrial pathway.11,21 Here, we
demonstrated that KP1339 in addition to apoptosis
induction potently arrests cell cycle progression in
G2/M phase which is accompanied by activation of
P38 signalling. P38 is a stress kinase, which has (compa-
rable to other MAP kinsases such as ERK) multiple
downstream targets and, consequently, is also involved
in the regulation of other stress-induced eﬀects such as
apoptosis induction.16,22 There is increasing evidence
that activation of P38 MAPK by stress stimuli may
not necessarily promote cell death but instead also
enhance cell survival through activation of a transient
G2/M cell cycle checkpoint and successful DNA dam-
age repair.18,19 This corroborates with our results that
treatment with sorafenib blocks KP1339-induced activa-
tion of the P38 signalling pathway. However, as speciﬁc
A
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Fig. 2. Impact of sorafenib on apoptosis-induction by KP1339 treatment. (A) Morphologic changes in Hep3B cells after 24 h drug treatment.
Photomicrographs shown were taken with a 10x objective and phase contrast settings using Nikon Eclipse TE300 (Nikon Instruments, Japan). (B)
Induction of apoptosis was determined in Hep3B cells after 24 h treatment. Nuclei of methanol/aceton-ﬁxed cells were stained by DAPI and
morphological features of 300–500 nuclei of at least two slides for each concentration were analysed. Percentages of normal and apoptotic/necrotic
cells are shown on the left panel, while percentages of mitotic cells are shown on the right panel. For statistical analyses 2-way Anova with
Bonferroni post correction was performed (***p < 0.001, **p < 0.01, *p < 0.05). (C) Cleavage of poly(ADP-ribosyl)polymerase (PARP) and caspase-
7 in Hep3B cells after 24 h drug treatment. (D) Induction of apoptosis and PARP cleavage was determined in VM-1 cells after 24 h treatment. (E)
Induction of apoptosis in VL-8 after 24 h treatment. For statistical analyses 2-way Anova with Bonferroni post correction was performed
(***p < 0.001, **p < 0.01, *p < 0.05).
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enhanced the anticancer activity of KP1339, it was con-
cluded that overcoming the KP1339-induced G2/M
arrest might not be the only mechanism underlying the
observed synergistic activity of KP1339 with sorafenib.
This is further supported by the observation of
(although distinctly weaker) synergistic activity of
KP1339 with the tyrosine kinase inhibitor sunitinib,
which shares several targets (VEGF, PDGF, KIT,FLT3 and RET) with sorafenib but does not inhibit
P38 phosphorylation.23 Consequently, additional mech-
anisms underlying the synergism of KP1339 with sorafe-
nib must exist.
Sorafenib as well as sunitinib have been recently
reported to inhibit several ATP-binding cassette (ABC)
transporters,10,24 which are responsible for multidrug
resistance due to enhanced eﬄux of diverse drugs includ-
ing doxorubicin, etoposide, taxol or imatinib.25 In addi-
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3372 P. Heﬀeter et al. / European Journal of Cancer 49 (2013) 3366–3375tion, both drugs are substrates for the non-ABC trans-
porter RLIP76 and were consequently suggested to
competitively interfere with the export of glutathione
conjugates.9,10 Thus, the impact of sorafenib on
KP1339 drug accumulation was considered as one pos-
sible mechanism underlying the observed synergism.
Indeed, sorafenib cotreatment distinctly increased intra-
cellular KP1339 levels, and KP1339 conversely
enhanced sorafenib accumulation. Moreover, thepanABC transporter inhibitor glibenclamide potently
increased the activity of sorafenib as well as KP1339.
These data indicate that KP1339 and sorafenib share a
common export mechanism. Notably, we have reported
before that the activity of KP1019 (the precursor of
KP1339) is not limited by ABCG2, ABCC1 and ABCC2
but the metal drug is a weak substrate for ABCB1.26
However, the synergistic activity of KP1339 with sorafe-
nib does not correlate with intrinsic ABCB1 expression
010
20
30
40
50
**
*
*
**
ng
 R
u 
/ 1
05
ce
lls
75 75 150 150 KP1339 
- 10 10- Sora 
75 150
5 5
Hep3B
0
20
40
60
80
100
**
**
**
**
ng
 R
u 
/ 1
05
ce
lls
75 75 150 150 KP1339 
- 10 10- Sora 
75 150
5 5
HepG2
0
10
20
30
40
**
**
*
***
ng
 R
u 
/ 1
05
ce
lls
75 75 150 150 KP1339 
- 10 10- Sora 
75 150
5 5
HCC1.1
A
0
10
20
30
ng
 R
u 
/ 1
05
ce
lls
75 75 150 150 KP1339 
- 10 10- Sora 
75 150
5 5
HCC1.2
*** 
He
p3
B
He
p3
B +
KP
13
39
VM
-1
VM
-1 
+ K
P1
33
9
0
50
100
150
200
µg
 S
or
af
en
ib
 / 
g 
Pr
ot
ei
n
B
0 50 100 150 200 250
0.0
0.5
1.0
Medium
50µM GLI
100µM GLI
***
***
***
***
***
***
******
***
KP1339 (µM)
C
ha
ng
e 
in
 v
ia
bi
lit
y
(-f
ol
d 
gr
ow
th
)
0.0 2.5 5.0 7.5 10.0
0.0
0.5
1.0
Medium
50µM GLI
100µM GLI
***
***
Sora (µM)
C
ha
ng
e 
in
 v
ia
bi
lit
y
(-
fo
ld
 g
ro
w
th
)
VM-1C 
Fig. 4. Eﬀects of the combination on the intracellular drug accumulation. (A) Eﬀect of sorafenib cotreatment on the total ruthenium (Ru) levels in
the indicated cell lines was determined after 3 h KP1339 exposure by inductively-coupled plasma mass spectroscopy (ICP-MS). Values given are
relative means and standard deviation (SD) from at least two independent experiments performed in triplicates. (B) Eﬀect of KP1339 cotreatment
on cytosolic sorafenib levels was determined by LC-MS measurements as described in Section 2. (C) VM-1 cells were treated with KP1339 or
sorafenib together with the indicated concentrations of GLI for 72 h. Viability was evaluated by MTT assay. Values given are means ± standard
deviations of one representative experiment performed in triplicates (***p < 0.001, **p < 0.01, *p > 0.05).
P. Heﬀeter et al. / European Journal of Cancer 49 (2013) 3366–3375 3373and no enhanced synergism was observed in ABCB1- or
ABCC1-overexpressing cell models as compared to the
parental cell lines (data not shown). Nevertheless, cancer
cells (especially hepatoma cells) express multiple ABC
transporters.27–29 Thus, the involvement of other ABC
transporters in the synergism of KP1339 with sorafenib
seems likely. Moreover, non-ABC transporter systems
such as RLIP76 also need to be considered30 especially
as additional functions in glutathione homoeostasis
and stress response were described.30–32 This is of inter-
est as Ru(III) compounds (such as KP1339) are known
for their interaction with cellular glutathione pools and,thus, the redox homoeostasis.3,20 Consequently, the role
of RLIP76 in the synergistic interaction of KP1339 with
sorafenib is the matter of ongoing investigations.
Altogether, we demonstrate a promising synergism of
the novel anticancer ruthenium compound KP1339 with
the multi-kinase inhibitor sorafenib, which is not only
based on inhibition of KP1339-induced G2/M arrest
and inhibition of P38 activation but also on conversely
enhanced intracellular accumulation of both drugs.
The multifaceted characteristics of this synergism are
probably also the reason why mostly synergistic or at
least additive eﬀects were observed in many cell lines
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Fig. 5. Anticancer activity of the KP1339/sorafenib combination in vivo. Hep3B xenografts were grown in Balb/c SCID mice and treated with
KP1339 (30 mg/kg; intravenous (i.v.); once a week) and/or sorafenib (25 mg/kg; p.o.; ﬁve consecutive days per week) for 2 weeks. (A) eﬀect of
treatment on tumour growth; (B) eﬀect of treatment on overall survival. (C) VM-1 xenografts were grown in Balb/c SCID mice and treated with
KP1339 (30 mg/kg; i.v.; once a week) and/or sorafenib (25 mg/kg; p.o.; ﬁve consecutive days per week) for 2 weeks. (D and E) Hep3B xenografts
were grown in Balb/c SCID mice and treated with the above described drug dose as indicated at the ﬁgure axis. At the last day of treatment tumour
samples were collected, paraﬃn-embedded and slices prepared. Percentages of apoptotic (D) and mitotic (E) cells in H/E-stained tumour sections
(n = 3 from n = 4 mice) were evaluated microscopically by counting. For statistical analyses 2-way Anova with Bonferroni post correction was
performed (*p < 0.05, **p < 0.01, ***p < 0.001) using Graph Pad Prism software.
3374 P. Heﬀeter et al. / European Journal of Cancer 49 (2013) 3366–3375independent of the original tumour type. This indicates
that occurrence of intrinsic resistance against the
KP1339 and sorafenib combination is unlikely and sug-
gests the further clinical development of KP1339 in com-
bination with sorafenib as a novel therapeutic strategy
in hepatoma and other solid tumours.Financial supports
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